title: A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.
abstract: OBJECTIVE
  The sustained virological response (SVR) rate of non-responders to peginterferon and ribavirin therapy (PR) is low for 24-week telaprevir-based triple combination therapy (T12PR24), compared to that of treatment-naïve patients or previous-treatment relapsers. This study investigated which characteristics of non-responders were associated with a better SVR rate to 48-week therapy (T12PR48).
  
  
  METHODS
  A total of 103 Japanese non-responders with genotype 1b chronic hepatitis C received telaprevir-based therapy. Among them, 81 patients (50 partial and 31 null responders) received T12PR24 and 22 (seven partial and 15 null responders) who agreed to the extended therapy received T12PR48.
  
  
  RESULTS
  Multivariate logistic regression analysis for SVR identified the interleukin-28B (IL28B) rs8099917 TT genotype (P = 0.0005, odds ratio [OR] = 10.38), extended rapid virological response (P = 0.0008, OR = 7.02), T12PR48 regimen (P = 0.0016, OR = 9.31) and previous partial responders (P = 0.0022, OR = 5.89). Among partial responders, the SVR rate did not differ significantly between T12PR48 (85.7%) and T12PR24 (70.0%). Among null responders, the SVR rate was significantly higher with T12PR48 than T12PR24 (66.7% vs 22.6%, P = 0.0037). Among patients with the IL28B non-TT genotype, the SVR rate was significantly higher with T12PR48 than T12PR24 (68.8% vs 37.7%, P = 0.0288). Moreover, among null responders with the non-TT genotype, the SVR rate was significantly higher with T12PR48 than T12PR24 (66.7% vs 9.1%, P = 0.0009).
  
  
  CONCLUSIONS
  T12PR48 improves the SVR rate in null responders, patients with the non-TT genotype, and null responders with a non-TT genotype.
authors.affiliation: Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, Japan.
authors.forename: Noritomo
authors.initials: N
authors.lastname: Shimada
authors.forename: Akihito
authors.initials: A
authors.lastname: Tsubota
authors.forename: Masanori
authors.initials: M
authors.lastname: Atsukawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Abe
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Ide
authors.forename: Koichi
authors.initials: K
authors.lastname: Takaguchi
authors.forename: Yoshimichi
authors.initials: Y
authors.lastname: Chuganji
authors.forename: Hidenori
authors.initials: H
authors.lastname: Toyoda
authors.forename: Kai
authors.initials: K
authors.lastname: Yoshizawa
authors.forename: Makiko
authors.initials: M
authors.lastname: Ika
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Sato
authors.forename: Keizo
authors.initials: K
authors.lastname: Kato
authors.forename: Takashi
authors.initials: T
authors.lastname: Kumada
authors.forename: Choitsu
authors.initials: C
authors.lastname: Sakamoto
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Aizawa
authors.forename: Michio
authors.initials: M
authors.lastname: Sata
keywords: 48-week therapy; chronic hepatitis C; non-responders; telaprevir